The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A dose-finding study of nanoparticle albumin-bound paclitaxel plus cisplatin in patients with metastatic nasophyngeal carcinomas.
Li Zhang
Consultant or Advisory Role - AstraZeneca (U); Pfizer (U); Roche (U)
Honoraria - AstraZeneca; Lilly; Roche
Research Funding - Celgene
Wenhua Liang
No relevant relationships to disclose
Yan Huang
No relevant relationships to disclose
Liping Zhao
No relevant relationships to disclose
Hongyun Zhao
No relevant relationships to disclose
Xuan Wu
No relevant relationships to disclose
Tao Qin
No relevant relationships to disclose